These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24530275)

  • 1. Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies.
    Taha DA; De Moor CH; Barrett DA; Gershkovich P
    Transl Res; 2014 Aug; 164(2):85-109. PubMed ID: 24530275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin-induced myopathy: the two faces of Janus.
    Arora R; Liebo M; Maldonado F
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):105-12. PubMed ID: 16891287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin safety: lessons from new drug applications for marketed statins.
    Jacobson TA
    Am J Cardiol; 2006 Apr; 97(8A):44C-51C. PubMed ID: 16581328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin induced myotoxicity.
    Sathasivam S
    Eur J Intern Med; 2012 Jun; 23(4):317-24. PubMed ID: 22560377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myotoxicity associated with lipid-lowering drugs.
    Baer AN; Wortmann RL
    Curr Opin Rheumatol; 2007 Jan; 19(1):67-73. PubMed ID: 17143099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.
    Nishimoto T; Ishikawa E; Anayama H; Hamajyo H; Nagai H; Hirakata M; Tozawa R
    Toxicol Appl Pharmacol; 2007 Aug; 223(1):39-45. PubMed ID: 17599378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does simvastatin cause more myotoxicity compared with other statins?
    Backes JM; Howard PA; Ruisinger JF; Moriarty PM
    Ann Pharmacother; 2009 Dec; 43(12):2012-20. PubMed ID: 19920157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin-induced myopathy: a review and update.
    Abd TT; Jacobson TA
    Expert Opin Drug Saf; 2011 May; 10(3):373-87. PubMed ID: 21342078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin myotoxicity: a review of genetic susceptibility factors.
    Needham M; Mastaglia FL
    Neuromuscul Disord; 2014 Jan; 24(1):4-15. PubMed ID: 24176465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies.
    Mohassel P; Mammen AL
    Muscle Nerve; 2013 Oct; 48(4):477-83. PubMed ID: 23519993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Muscle problems due to statins: underestimated].
    Janssen SP; Smulders YM; Gerdes VE; Visseren FL
    Ned Tijdschr Geneeskd; 2010; 154():A1684. PubMed ID: 21435278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Muscle-related adverse effects of statins].
    Pohjola-Sintonen S; Julkunen H
    Duodecim; 2014; 130(16):1622-7. PubMed ID: 25269368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymptomatic statin-induced rhabdomyolysis after long-term therapy with the hydrophilic drug pravastatin.
    Schindler C; Thorns M; Matschke K; Tugtekin SM; Kirch W
    Clin Ther; 2007 Jan; 29(1):172-6. PubMed ID: 17379057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing statin-induced muscle toxicity in a lipid clinic.
    Blaier O; Lishner M; Elis A
    J Clin Pharm Ther; 2011 Jun; 36(3):336-41. PubMed ID: 21414023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.
    Banach M; Rizzo M; Toth PP; Farnier M; Davidson MH; Al-Rasadi K; Aronow WS; Athyros V; Djuric DM; Ezhov MV; Greenfield RS; Hovingh GK; Kostner K; Serban C; Lighezan D; Fras Z; Moriarty PM; Muntner P; Goudev A; Ceska R; Nicholls SJ; Broncel M; Nikolic D; Pella D; Puri R; Rysz J; Wong ND; Bajnok L; Jones SR; Ray KK; Mikhailidis DP
    Expert Opin Drug Saf; 2015 Jun; 14(6):935-55. PubMed ID: 25907232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
    Kostapanos MS; Milionis HJ; Elisaf MS
    Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipidomics-based safety biomarkers for lipid-lowering treatments.
    Laaksonen R; Jänis MT; Oresic M
    Angiology; 2008; 59(2 Suppl):65S-8S. PubMed ID: 18632766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced myopathies.
    Klopstock T
    Curr Opin Neurol; 2008 Oct; 21(5):590-5. PubMed ID: 18769254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin myopathy: a review of recent progress.
    Mammen AL; Amato AA
    Curr Opin Rheumatol; 2010 Nov; 22(6):644-50. PubMed ID: 20827205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.